{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:51:37Z","timestamp":1790142697643,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008909","name":"Universitatea de Medicin\u0103 \u015fi Farmacie din T\u00eergu Mure\u0219","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154189","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:17:39Z","timestamp":1782170259000},"page":"154189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib"],"prefix":"10.1016","volume":"829","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-2335","authenticated-orcid":false,"given":"Hoai Thu","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1807-2067","authenticated-orcid":false,"given":"Nguyen Bao","family":"Nghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu Diem","family":"My","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Anh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Chi","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6784-2438","authenticated-orcid":false,"given":"Bui Minh","family":"Tri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-5199","authenticated-orcid":false,"given":"Vo Van Thanh","family":"Niem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huynh Anh","family":"Phuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154189_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"10.1016\/j.bbrc.2026.154189_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3759179","article-title":"A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR+\/HER2- metastatic breast cancer","author":"Anderson","year":"2020","journal-title":"Int. J. Breast Cancer"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154189_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers17010016","article-title":"New emerging therapies targeting PI3K\/AKT\/mTOR\/PTEN pathway in hormonal receptor-positive and HER2-Negative breast cancer\u2014current state and molecular pathology perspective","volume":"17","author":"Liu","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bbrc.2026.154189_bib4","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/j.clbc.2020.02.002","article-title":"Targeting PIK3CA alterations in hormone receptor-positive, human epidermal growth factor Receptor-2\u2013Negative advanced breast cancer: new therapeutic approaches and practical considerations","volume":"20","author":"Schwartzberg","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbrc.2026.154189_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1082915","article-title":"Evaluation of PIK3CA mutations in advanced ER+\/HER2-breast cancer in Portugal - U-PIK project","volume":"10","author":"Peixoto","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbrc.2026.154189_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1082915","article-title":"Evaluation of PIK3CA mutations in advanced ER+\/HER2-breast cancer in Portugal \u2013 U-PIK project","volume":"10","author":"Peixoto","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"17","key":"10.1016\/j.bbrc.2026.154189_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70101","article-title":"PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+\/HER2- breast cancer","volume":"13","author":"Ter\u00e1n","year":"2024","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154189_bib8","article-title":"Oncogenic activation of PIK3CA in cancers: emerging targeted therapies in precision oncology","volume":"12","author":"Wang","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbrc.2026.154189_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-025-02180-4","article-title":"Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs","volume":"10","author":"Gremke","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154189_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102861","article-title":"PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer","volume":"132","author":"Hao","year":"2025","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154189_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/medicina61030518","article-title":"The effect and treatment of PIK3CA mutations in breast cancer: current understanding and future directions","volume":"61","author":"Cho","year":"2025","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"9","key":"10.1016\/j.bbrc.2026.154189_bib12","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3390\/cancers14092161","article-title":"PI3K inhibitors in advanced breast cancer: the past, the present, new challenges and future perspectives","volume":"14","author":"Fuso","year":"2022","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.bbrc.2026.154189_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbrc.2026.154189_bib14","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res. : Offic. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154189_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4143\/crt.2024.1195","article-title":"Differential efficacy of Alpelisib by PIK3CA Mutation site in head and neck squamous cell carcinoma: an analysis from the KCSG HN 15-16 TRIUMPH trial","volume":"57","author":"Kim","year":"2025","journal-title":"Cancer Res. Treatment"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154189_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgeb.2017.10.002","article-title":"The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer","volume":"16","author":"Desriani","year":"2018","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154189_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3233\/BD-240005","article-title":"A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis","volume":"43","author":"Debouki-Joudi","year":"2024","journal-title":"Breast Dis."},{"key":"10.1016\/j.bbrc.2026.154189_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.mgene.2020.100709","article-title":"PIK3CA mutation profiling in Vietnamese patients with breast cancer","volume":"25","author":"Vuong","year":"2020","journal-title":"Meta Gene"},{"key":"10.1016\/j.bbrc.2026.154189_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27044-6","article-title":"Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations","volume":"8","author":"Leontiadou","year":"2018","journal-title":"Sci. Rep."},{"issue":"46","key":"10.1016\/j.bbrc.2026.154189_bib20","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215621119","article-title":"Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3K\u03b1","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"13","key":"10.1016\/j.bbrc.2026.154189_bib21","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1039\/C9SC05903B","article-title":"Unravelling the effect of the E545K mutation on PI3K\u03b1 kinase","volume":"11","author":"Galdadas","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bbrc.2026.154189_bib22","first-page":"43","article-title":"Structural effects of oncogenic PI3K\u03b1 mutations","volume":"347","author":"Gabelli","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"9","key":"10.1016\/j.bbrc.2026.154189_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4161\/cc.7.9.5817","article-title":"Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha\/p85alpha","volume":"7","author":"Huang","year":"2008","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"key":"10.1016\/j.bbrc.2026.154189_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41467-023-35789-6","article-title":"Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus","volume":"14","author":"Jenkins","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154189_bib28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann. Oncol. : Offic. J. Euro. Soc. Med. Oncol."},{"key":"10.1016\/j.bbrc.2026.154189_bib29","article-title":"Elacestrant in metastatic breast cancer: current advancements and future perspectives","author":"Sahin","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"7","key":"10.1016\/j.bbrc.2026.154189_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.bbrc.2026.154189_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102198","article-title":"Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis","volume":"8","author":"Rizzo","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbrc.2026.154189_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154189_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154189_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103023","article-title":"Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives","volume":"140","author":"Di Lauro","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2026.154189_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1663823","article-title":"Subtype-specific prognostic implications of plasma-detected PIK3CA mutations in Vietnamese breast cancer patients","volume":"15","author":"Thao","year":"2025","journal-title":"Front. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26009538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26009538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:54:57Z","timestamp":1786625697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26009538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S0006291X26009538"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154189","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154189"}}